|
| Press Releases |
|
 |
|
| Wednesday, September 5, 2018 |
|
|
NANOBIOTIX half year results for the six months ended June 30, 2018 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended June 30 2018, from the consolidated financial statements at June 30, 2018 that have been reviewed by the supervisory board dated September 4, 2018. more info >> |
|
| Friday, July 27, 2018 |
|
|
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company launched a non-dilutive financial partnership with the European Investment Bank (EIB) to boost its research, development and innovation activities. more info >> |
|
| Friday, June 22, 2018 |
|
|
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today positive topline results of the Phase II/III act.in.sarc trial evaluating NBTXR3 in Soft Tissue Sarcoma (STS). more info >> |
|
| Wednesday, June 6, 2018 |
|
|
NANOBIOTIX' Management Statement on Recent Share Price Variation |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, communicates today regarding the recent evolution of its share price. more info >> |
|
| Friday, May 4, 2018 |
|
|
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced today that it is launching a research collaboration with Weill Cornell Medicine to begin nonclinical studies of NBTXR3's mechanism of action. more info >> |
|
| Wednesday, April 18, 2018 |
|
|
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that preclinical data evaluating the activation of the cGAS-STING pathway by NBTXR3 has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 in Chicago, Illinois (April 14-18, 2018). more info >> |
|
| Wednesday, April 11, 2018 |
|
|
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston TX, to work on NBTXR3, Nanobiotix's lead product. more info >> |
|
| Friday, March 30, 2018 |
|
|
Nanobiotix 2017 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017. more info >> |
|
| Monday, January 22, 2018 |
|
|
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of intermediate data on the safety and feasibility in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and liver metastasis from other tumors. more info >> |
|
| Thursday, January 11, 2018 |
|
|
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it will begin a pre-clinical collaboration with Providence Cancer Institute to study Nanobiotix's lead product, NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors and activation by radiotherapy. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
The USPA and U.S. Polo Assn. Celebrate 135th Anniversary with Global Sport and Fashion Events and Launch of "Born to Play"
Jan 30, 2025 20:00 HKT/SGT
|
|
|
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
|
|
|
Honda、2024年12月度 四輪車 生産・販売・輸出実績を発表
Jan 30, 2025 15:00: JST
|
|
|
トヨタ、2024年 年間（1月－12月）販売・生産・輸出実績を発表
Jan 30, 2025 15:00: JST
|
|
|
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
|
|
|
三菱重工サーマルシステムズ、2024年度省エネ大賞で「資源エネルギー庁長官賞」を受賞
Jan 30, 2025 14:00: JST
|
|
|
MHI Thermal Systems Receives 2024 Agency for Natural Resources and Energy Commissioner's Award from ECCJ for TEJ35AM Electric-Driven Transport Refrigeration Unit Integrated with Isuzu's ELF EV
Jan 30, 2025 14:13 JST
|
|
|
三菱造船、インドネシア海上保安機構向けの巡視船を受注
Jan 30, 2025 12:00: JST
|
|
|
富士通、スペイン大手の労働災害・疾病相互保険会社ASEPEYO様の保険給付に関わるシステムのモダナイゼーションを支援
Jan 30, 2025 12:00: JST
|
|
|
Mitsubishi Shipbuilding Receives Order for an Offshore Patrol Vessel from the Indonesian Maritime Security Agency
Jan 30, 2025 12:35 JST
|
|
|
Fujitsu and Asepeyo collaborate to modernise the management of occupational benefits and contingencies
Jan 30, 2025 11:56 JST
|
|
|
Fourth Star Launches Immersive Media Streaming Platform
Jan 30, 2025 10:30 HKT/SGT
|
|
|
Suzuki, Daihatsu, and Toyota Decide on the Release Schedule for Mini-Commercial Van Electric Vehicles
Jan 30, 2025 10:56 JST
|
|
|
Supply Chain Specialists OMP Strengthen Leadership to Support Strategic Growth
Jan 30, 2025 09:48 HKT/SGT
|
|
|
A Quantum Leap into Uplisting: Spectral Capital and the Next Generation of Computing
Jan 29, 2025 22:47 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
